Chiesi Global Rare Diseases committed up to $115 million to partner with Arbor Biotechnologies on an in vivo CRISPR gene‑editing candidate for primary hyperoxaluria type 1 (PH1) and other liver targets. The collaboration gives Chiesi access to Arbor’s Cas12‑style in vivo editing platform and funds ongoing Phase I/II work, while Arbor retains research control and potential downstream option economics. The pact marks Chiesi’s entry into genetic medicines and expands industry interest in single‑dose, liver‑directed gene editing.